cd69 (Bioss)
Structured Review

Cd69, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd69/product/Bioss
Average 94 stars, based on 12 article reviews
Images
1) Product Images from "Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus"
Article Title: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus
Journal: British Journal of Cancer
doi: 10.1038/s41416-024-02583-0
Figure Legend Snippet: a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and CD69. Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.
Techniques Used: Staining, Immunohistochemical staining

![Assessing mCD69 expression in primary mouse T cells using flow cytometry and [89Zr]-DFO-H1.2F3 uptake. A, Scheme of <t>CD69</t> antibody binding: H1.2F3 monoclonal anti-CD69 binds to mCD69 on the surface of activated primary mouse T cells and other immune cells. B, Scheme of CD69 imaging: CD69 can be used as a biomarker to distinguish immunologically active tumors of mice that respond to checkpoint blockade (CBP) therapy (responders) from the tumors of mice that do not respond to therapy (nonresponders). C, Ex vivo flow cytometry analysis of CD69 expression for primary mouse T cells treated with PMA/ionomycin or untreated primary mouse T cells. D, Ex vivo [89Zr]-DFO-H1.2F3 uptake for primary mouse T cells treated with 50 ng/mL PMA and 1 μg/mL ionomycin, untreated primary mouse T cells, and CT26 cells. Uptake was measured on γ-counter and normalized to percent injected dose per million cells (% ID/106 cells). Error bars, SD.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_6840/pmc10026840/pmc10026840__nihms-1877164-f0001.jpg)